Management of DAPT in ICAS Stroke Patients Who Develop Atrial Fibrillation

Rationale for Immediate Transition

The American College of Cardiology provides clear guidance for patients with cerebrovascular disease on antiplatelet therapy who develop atrial fibrillation requiring anticoagulation, recommending stopping all antiplatelet therapy and treating with an oral anticoagulant (OAC) alone when considered safe from the perspective of hemorrhagic transformation, typically between 2 and 14 days following an acute event 1, 2, 3.
For patients on antiplatelet therapy for prior transient ischemic attack or stroke who develop atrial fibrillation requiring OAC therapy, the pathway recommends stopping all antiplatelet therapy and treating with an OAC alone when considered safe from the perspective of hemorrhagic transformation, typically between 2 and 14 days following an acute event 1, 2, 3.

The American College of Cardiology recommends stopping aspirin immediately to reduce bleeding risk from triple therapy, continuing the P2Y12 inhibitor (preferably clopidogrel), and starting a direct oral anticoagulant (DOAC) without waiting to complete the 90-day dual antiplatelet therapy (DAPT) course in patients with intracranial atherosclerotic stenosis (ICAS) who develop atrial fibrillation 1, 2, 4.
The American College of Cardiology recommends continuing clopidogrel with the DOAC until completing the originally planned 90-day period from the index stroke in ICAS patients, providing adequate stroke prevention from atrial fibrillation via anticoagulation and continued protection against arterial thrombosis in the stenotic intracranial vessel 1, 3.

The American College of Cardiology recommends initiating anticoagulation between 2 and 14 days following the acute stroke event, with earlier initiation for smaller infarcts and later initiation for larger infarcts, to balance the risk of hemorrhagic transformation and cardioembolic stroke 1, 2, 3.

The American College of Cardiology strongly prefers a DOAC over warfarin due to lower intracranial hemorrhage risk, which is particularly important in patients with recent stroke, and recommends standard dosing unless dose-reduction criteria are met 1, 2, 6.

The American College of Cardiology recommends assessing and addressing modifiable bleeding risk factors, such as using proton pump inhibitors for gastrointestinal protection, optimizing blood pressure control, avoiding nonsteroidal anti-inflammatory drugs (NSAIDs) and other medications that increase bleeding risk, and monitoring renal function and adjusting DOAC dosing accordingly 6.